Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications

[1] Helmy KY(2013)Cancer immunotherapy: accomplishments to date and future promise Ther Deliv 4 1307-1320

[2] Patel SA(2019)Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors Drug Metab Rev 51 562-569

[3] Nahas GR(2016)Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials Cancer Chemother Pharmacol 78 167-171

[4] Gabora K(2016)Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses PLoS ONE 11 373-398

[5] Piciu A(2000)Protein tyrosine kinase structure and function Annu Rev Biochem 69 174-185

[6] Bădulescu IC(2020)Receptor tyrosine kinase activation: from the ligand perspective Curr Opin Cell Biol 63 1383-1391

[7] Bilen MA(2012)The Capicua repressor—a general sensor of RTK signaling in development and disease J Cell Sci 125 117-123

[8] Patel A(2007)Receptor tyrosine kinases: mechanisms of activation and signaling Curr Opin Cell Biol 19 2395-2400

[9] Hess KR(2020)Reported cardiovascular toxicity associated with paclitaxel antineoplastic drugs and literature analysis Chin J New Drugs 29 917-927

[10] Shu M(2017)Long-term outcomes of imatinib treatment for chronic myeloid leukemia N Engl J Med 376 239-246

[1] Helmy KY(2013)Cancer immunotherapy: accomplishments to date and future promise Ther Deliv 4 1307-1320

[2] Patel SA(2019)Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors Drug Metab Rev 51 562-569

[3] Nahas GR(2016)Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials Cancer Chemother Pharmacol 78 167-171

[4] Gabora K(2016)Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses PLoS ONE 11 373-398

[5] Piciu A(2000)Protein tyrosine kinase structure and function Annu Rev Biochem 69 174-185

[6] Bădulescu IC(2020)Receptor tyrosine kinase activation: from the ligand perspective Curr Opin Cell Biol 63 1383-1391

[7] Bilen MA(2012)The Capicua repressor—a general sensor of RTK signaling in development and disease J Cell Sci 125 117-123

[8] Patel A(2007)Receptor tyrosine kinases: mechanisms of activation and signaling Curr Opin Cell Biol 19 2395-2400

[9] Hess KR(2020)Reported cardiovascular toxicity associated with paclitaxel antineoplastic drugs and literature analysis Chin J New Drugs 29 917-927

[10] Shu M(2017)Long-term outcomes of imatinib treatment for chronic myeloid leukemia N Engl J Med 376 239-246